CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination
K Früh, L Picker - Current opinion in immunology, 2017 - Elsevier
K Früh, L Picker
Current opinion in immunology, 2017•ElsevierHighlights•Effector memory T cell (T EM) inducing vaccines represent a novel paradigm in
vaccine development that enables the early intercept of incoming or reactivating pathogens.•
Cytomegalovirus (CMV)-based vectors elicit and maintain high frequency T EM to inserted
antigens.•Rhesus CMV-based vaccines control and clear highly pathogenic simian
immunodeficiency virus (SIV).•Specific deletions in the RhCMV genome permit the
programming of CD8+ T cells to four different, non-overlapping sets of epitopes restricted by …
vaccine development that enables the early intercept of incoming or reactivating pathogens.•
Cytomegalovirus (CMV)-based vectors elicit and maintain high frequency T EM to inserted
antigens.•Rhesus CMV-based vaccines control and clear highly pathogenic simian
immunodeficiency virus (SIV).•Specific deletions in the RhCMV genome permit the
programming of CD8+ T cells to four different, non-overlapping sets of epitopes restricted by …
Highlights
- Effector memory T cell (T EM) inducing vaccines represent a novel paradigm in vaccine development that enables the early intercept of incoming or reactivating pathogens.
- Cytomegalovirus (CMV)-based vectors elicit and maintain high frequency T EM to inserted antigens.
- Rhesus CMV-based vaccines control and clear highly pathogenic simian immunodeficiency virus (SIV).
- Specific deletions in the RhCMV genome permit the programming of CD8+ T cells to four different, non-overlapping sets of epitopes restricted by MHC-I, MHC-II or MHC-E molecules.
- CMV-based vaccines can be designed to elicit CD8+ T cell responses that exploit any given pathogen's immunologic vulnerability and thereby provide optimal protection.
Vectors based on cytomegalovirus (CMV) represent a novel vaccine platform that maintains high frequencies of non-exhausted effector memory T cells in both CMV sero-positive and sero-negative individuals. In non-human primate models, CMV vectored vaccines provide unprecedented protection against simian immunodeficiency virus (SIV). Moreover, CMV vectors can be genetically altered to program highly diverse CD8+ T cell responses that differ in their epitope targeting including conventional, MHC-I restricted CD8+ T cells as well as unconventional CD8+ T cells restricted by MHC class II or non-polymorphic MHC-E. By modifying cytomegaloviral determinants that control unconventional T cell priming it is possible to uniquely tailor the CD8+ T cell response for each individual disease target in order to maximize prophylactic or therapeutic protection.
Elsevier